Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

Age-Related Changes in Body Composition

Lead Sponsor:

National Institute on Aging (NIA)

Conditions:

Hypertension

Atherosclerosis

Eligibility:

All Genders

50-90 years

Brief Summary

Background: \- Advancing age is associated with greater risk of heart disease. High blood pressure and hardening of the arteries also have more complications with age. Studies suggest that age-relate...

Detailed Description

Advancing age is associated with an increasing prevalence, incidence, and complications of cardiovascular diseases, particularly hypertension and atherosclerosis. The reasons why age is associated wit...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA: (both Group A and Group B):
  • Age 50-90 years
  • Body mass index greater than or equal to 20 and less than or equal to 35
  • Weight is less than 300 lbs
  • In addition, for CAD participants (Group B):
  • Catheterization-documented coronary artery disease, defined as greater than or equal to 70% stenosis in a major epicardial coronary artery, or greater than or equal to 50% stenosis of the left main coronary artery OR
  • Prior myocardial infarction defined by ischemic symptoms associated with ECG changes and enzyme elevation.
  • In addition, for CAD participants in whom arterial and hepatic vein inflammatory mediators will be obtained:
  • \- Scheduled for clinically indicated right or left heart catheterization, no contraindication for the procedure, and consented to the research procedure.
  • Exclusion criteria
  • Known inflammatory disease
  • Known liver disease
  • Abnormal liver function tests defined by enzyme rise to greater than three times the upper limit of normal.
  • Contraindications to the performance of MRI scans
  • Chronic use of anti-inflammatory agents other than low dose aspirin (81mg). Chronic use is defined here as the inability to stop taking their anti-inflammatory agent for at least one week before starting this study
  • Pregnant or lactating
  • In addition, for BLSA participants:
  • \- Known coronary artery disease by prior history, examination, or resting or stress electrocardiogram testing.
  • In addition, for CAD participants undergoing arterial and hepatic vein inflammatory mediator sampling:
  • Receiving therapy with heparin, a glycoprotein IIB/IIIA inhibitor, or bivalirudin
  • History of atrial fibrillation
  • Presence of an inferior vena cava filter
  • Deep venous thrombosis
  • Active infection.

Exclusion

    Key Trial Info

    Start Date :

    January 2 2012

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 13 2017

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT01517113

    Start Date

    January 2 2012

    End Date

    October 13 2017

    Last Update

    April 5 2018

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Johns Hopkins University

    Baltimore, Maryland, United States, 21205

    2

    National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland, United States, 21224